How best to handle the evidence in a cost-effectiveness analysis of TAVI in the UK
نویسندگان
چکیده
Methods A decision analytical model, incorporating a short–term decision tree and long-term Markov model were constructed. The use of Monte Carlo simulation and Value of Information analysis enables both the cost-effectiveness of TAVI to be estimated, based on the existing information, and the value of, and requirements for, further evidence collection to be determined. The model allows for the heterogeneous patient population by considering different three patient risk cohorts (low, medium and high). Initially the model was populated using the best available literature; then updated when RCT results became available. However, the trial data did not fully reflect UK practice as such the model was updated with UK Registry data. Probabilistic analysis is undertaken at each stage and results are presented for the costeffectiveness and the value of undertaking further research.
منابع مشابه
How Useful Are Early Economic Models?; Comment on “Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling”
Early economic modelling has long been recommended to aid research and development (R&D;) decisions in medical innovation, although they are less frequently published and critically appraised. A review of 30 innovations by Grutters et al provides an opportunity to evaluate how early models are used in practice. The evidence of early models can be used to inform two types...
متن کاملUse of Evidence-Informed Deliberative Processes – Learning by Doing; Comment on “Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe”
The article by Oortwijn, Jansen, and Baltussen (OJB) is much more important than it appears because, in the absence of any good general theory of “evidence-informed deliberative processes” (EDP) and limited evidence of how they might be shaped and work in institutionalising health technology assessment (HTA), the best approach seems to be to accumulate the experience of...
متن کاملHealth Technology Assessment: Global Advocacy and Local Realities; Comment on “Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness”
Cost-effectiveness analysis (CEA) can help countries attain and sustain universal health coverage (UHC), as long as it is context-specific and considered within deliberative processes at the country level. Institutionalising robust deliberative processes requires significant time and resources, however, and countries often begin by demanding evidence (including local CEA evidence as well as evi...
متن کاملUse of Cost-Effectiveness Data in Priority Setting Decisions: Experiences from the National Guidelines for Heart Diseases in Sweden
Background The inclusion of cost-effectiveness data, as a basis for priority setting rankings, is a distinguishing feature in the formulation of the Swedish national guidelines. Guidelines are generated with the direct intent to influence health policy and support decisions about the efficient allocation of scarce healthcare resources. Certain medical conditions may be given higher priority ran...
متن کاملThe Bright Elusive Butterfly of Value in Health Technology Development; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies”
The current system of health technology development is characterised by multiple misalignments. The “supply” side (innovation policy-makers, entrepreneurs, investors) and the “demand” side (health policy-makers, regulators, health technology assessment, purchasers) operate under different – and conflicting – logics. The system is less a “pathway” than an unstable ecosystem of multiple interacti...
متن کامل